Ibrutinib combos target hard-to-treat CML and MCL at ASH 2022 R&D, Therapeutics Co-developed by J&J’s Janssen and AbbVie’s Pharmacyclics, ibrutinib stood out across several presentations at the 64th American Society of Hematology (ASH) annual meeting Saturday and Sunday. Read more December 12, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2021/03/Janssens-Psoriatic-Arthritis-Drug-Proves-Long-Term-Efficacy-in-Two-Year-Trial-BioSpace-3-16-21.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-12-12 09:45:102022-12-12 10:39:24Ibrutinib combos target hard-to-treat CML and MCL at ASH 2022
